Fresh off of a European approval for a subcutaneous version of Saphnelo, AstraZeneca is doubling down on the benefits of the ...

Chief among the factors driving a sense of optimism among the biopharma leaders was the unfreezing of the biotech investing ...

After shepherding the company through its first approval and the successful launch of blockbuster autoimmune drug Vyvgart, ...

The U.S. previously recommended more childhood vaccines than any peer nation, according to the HHS, which pointed out that ...

A positive top-line readout from a phase 3 trial has emboldened Incyte to seek the FDA’s blessing for the company’s Monjuvi ...

Shortly after scoring a historic FDA nod for its Wegovy pill, Novo Nordisk is off to the races with the oral obesity med’s ...

Initiatives from former President Joe Biden and current President Donald Trump have been effective in reducing the prices of ...

Daiichi Sankyo plans to splash out some 300 billion yen ($1.9 billion) on Enhertu manufacturing facilities across the globe, ...

A recent survey shows that healthcare professionals have varied feelings on the direct-to-patient (DTP) drug sale platforms ...

Bausch + Lomb has partnered with the glaucoma community once again, launching its fifth annual fundraising challenge and ...

Welcome to Fierce Pharma's regulatory tracker for the first half of 2026. | In this tracker, Fierce Pharma is recording the ...

The emergence of next-generation KRAS G12C inhibitors has led Verastem Oncology to change course. | The emergence of ...